Structure Therapeutics (GPCR) Common Equity (2022 - 2026)

Structure Therapeutics' Common Equity history runs 5 years deep, the most recent figure standing at $1.4 billion for Q1 2026.

• On a quarterly basis, Common Equity rose 75.48% year-over-year to $1.4 billion in Q1 2026; TTM through Mar 2026 was $1.4 billion, a 75.48% increase from a year earlier, with the FY2025 full-year figure at $1.5 billion, up 75.34% from the prior year.
• Common Equity slipped to $1.4 billion in Q1 2026 per GPCR's latest filing, from $1.5 billion in the prior quarter.
• Across five years, Common Equity topped out at $1.5 billion in Q4 2025 and bottomed at -$115.1 million in Q4 2022.
• The 5-year median for Common Equity is $453.0 million (2023), against an average of $538.3 million.
• Across the five-year window, Common Equity jumped 493.4% in 2023 and slipped 16.17% in 2025, its largest moves.
• Year by year, Common Equity stood at -$115.1 million in 2022, then soared by 493.4% to $453.0 million in 2023, then soared by 90.93% to $864.8 million in 2024, then soared by 75.34% to $1.5 billion in 2025, then retreated by 4.57% to $1.4 billion in 2026.
• Per Business Quant, the three latest GPCR Common Equity figures stand at $1.4 billion (Q1 2026), $1.5 billion (Q4 2025), and $770.0 million (Q3 2025).